Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

carbapenem resistance

  • A Matched Case-Case-Control Study of the Impact of Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing Carbapenem-Resistant <em>Enterobacteriaceae</em> in Japan
    Clinical Therapeutics
    A Matched Case-Case-Control Study of the Impact of Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae in Japan

    IMP-type carbapenemase, found in various Gram-negative bacteria, has been increasingly detected worldwide. We aimed to study the outcomes and risk factors for acquisition of IMP-type carbapenemase-producing carbapenem-resistant Enterobacteriaceae (IMP-CRE), as this has not been evaluated in detail.

    Sho Saito, Kayoko Hayakawa, Shinya Tsuzuki, Masahiro Ishikane, Maki Nagashima, Kazuhisa Mezaki, Yuko Sugiki, Taichi Tajima, Nobuaki Matsunaga, Satoshi Ide, Noriko Kinoshita, Yoshiki Kusama, Yumiko Fujitomo, Takato Nakamoto, Yuta Toda, Mitsuo Kaku, Eiichi N. Kodama, Norio Ohmagari
  • <em>In Vitro</em> Pharmacodynamics of Fosfomycin against Carbapenem-Resistant <span class="named-content genus-species" id="named-content-1">Enterobacter cloacae</span> and <span class="named-content genus-species" id="named-content-2">Klebsiella aerogenes</span>
    Experimental Therapeutics
    In Vitro Pharmacodynamics of Fosfomycin against Carbapenem-Resistant Enterobacter cloacae and Klebsiella aerogenes

    The increase of carbapenem-resistant Enterobacterales (CRE) and lack of therapeutic options due to the scarcity of new antibiotics has sparked interest toward the use of intravenous fosfomycin against systemic CRE infections. We aimed to investigate the in vitro pharmacodynamics of fosfomycin against carbapenem-resistant Enterobacter cloacae and...

    Tze-Peng Lim, Jocelyn Qi-Min Teo, Audrey Wei-Ling Goh, Si-Xuan Tan, Tse-Hsien Koh, Winnie Hui-Ling Lee, Yiying Cai, Thuan-Tong Tan, Andrea Lay-Hoon Kwa
  • Open Access
    Reduced Susceptibility to Carbapenems in a <span class="named-content genus-species" id="named-content-1">Klebsiella pneumoniae</span> Clinical Isolate Producing SCO-1 and CTX-M-15 β-Lactamases Together with OmpK35 and OmpK36 Porin Deficiency
    Letter to the Editor
    Reduced Susceptibility to Carbapenems in a Klebsiella pneumoniae Clinical Isolate Producing SCO-1 and CTX-M-15 β-Lactamases Together with OmpK35 and OmpK36 Porin Deficiency
    Carolina Venditti, Ornella Butera, Anna Proia, Luigi Rigacci, Bruno Mariani, Gabriella Parisi, Francesco Messina, Alessandro Capone, Carla Nisii, Antonino Di Caro
  • Open Access
    Efficacy of Antibiotic Combinations against Multidrug-Resistant <span class="named-content genus-species" id="named-content-1">Pseudomonas aeruginosa</span> in Automated Time-Lapse Microscopy and Static Time-Kill Experiments
    Clinical Therapeutics
    Efficacy of Antibiotic Combinations against Multidrug-Resistant Pseudomonas aeruginosa in Automated Time-Lapse Microscopy and Static Time-Kill Experiments

    Antibiotic combination therapy is used for severe infections caused by multidrug-resistant (MDR) Gram-negative bacteria, yet data regarding which combinations are most effective are lacking. This study aimed to evaluate the in vitro efficacy of polymyxin B in combination with 13 other antibiotics against four clinical strains of MDR Pseudomonas aeruginosa. We...

    Anna Olsson, Pikkei Wistrand-Yuen, Elisabet I. Nielsen, Lena E. Friberg, Linus Sandegren, Pernilla Lagerbäck, Thomas Tängdén
  • Activity of Imipenem-Relebactam against Carbapenem-Resistant <span class="named-content genus-species" id="named-content-1">Escherichia coli</span> Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region
    Epidemiology and Surveillance
    Activity of Imipenem-Relebactam against Carbapenem-Resistant Escherichia coli Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region

    Imipenem-relebactam (I-R) is a recently developed carbapenem–beta-lactamase inhibitor combination agent that can overcome carbapenem resistance, which has now emerged in Escherichia coli, including sequence type 131 (ST131) and its fluoroquinolone-resistant H30R subclone, the leading cause of extraintestinal...

    Brian D. Johnston, Paul Thuras, Stephen B. Porter, Melissa Anacker, Brittany VonBank, Paula Snippes Vagnone, Medora Witwer, Mariana Castanheira, James R. Johnson
  • Multiple Copies of <em>bla</em><sub>NDM-5</sub> Located on Conjugative Megaplasmids from Porcine <span class="named-content genus-species" id="named-content-1">Escherichia coli</span> Sequence Type 218 Isolates
    Letter to the Editor
    Multiple Copies of blaNDM-5 Located on Conjugative Megaplasmids from Porcine Escherichia coli Sequence Type 218 Isolates
    Hong Yao, Aijuan Li, Runhao Yu, Stefan Schwarz, Huiyue Dong, Xiang-Dang Du
  • Distinct Mechanisms of Dissemination of NDM-1 Metallo-β-Lactamase in <em>Acinetobacter</em> Species in Argentina
    Epidemiology and Surveillance
    Distinct Mechanisms of Dissemination of NDM-1 Metallo-β-Lactamase in Acinetobacter Species in Argentina

    A 4-year surveillance of carbapenem-resistant Acinetobacter spp. isolates in Argentina identified 40 strains carrying blaNDM-1. Genome sequencing revealed that most were Acinetobacter baumannii, whereas seven represented other Acinetobacter spp. The A. baumannii...

    Mark D. Adams, Fernando Pasteran, German M. Traglia, Jasmine Martinez, Fanny Huang, Christine Liu, Jennifer S. Fernandez, Carolina Lopez, Lisandro J. Gonzalez, Ezequiel Albornoz, Alejandra Corso, Alejandro J. Vila, Robert A. Bonomo, Maria Soledad Ramirez
  • Free
    Coinfections of Two Strains of NDM-1- and OXA-232-Coproducing <span class="named-content genus-species" id="named-content-1">Klebsiella pneumoniae</span> in a Kidney Transplant Patient
    Challenging Clinical Case in Antimicrobial Resistance
    Coinfections of Two Strains of NDM-1- and OXA-232-Coproducing Klebsiella pneumoniae in a Kidney Transplant Patient

    We report here a fatal case of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in a renal transplant patient without a travel history in the prior year, from whom 2 genetically different CRKP (sequence type 14 [ST14] and ST2497) strains carrying the same plasmids and antimicrobial resistance genes, including blaNDM-1, bla...

    Deisy A. Contreras, Sean P. Fitzwater, Deepa D. Nanayakkara, Joanna Schaenman, Grace M. Aldrovandi, Omai B. Garner, Shangxin Yang
  • High-Level Carbapenem Resistance in OXA-232-Producing <span class="named-content genus-species" id="named-content-1">Raoultella ornithinolytica</span> Triggered by Ertapenem Therapy
    Mechanisms of Resistance
    High-Level Carbapenem Resistance in OXA-232-Producing Raoultella ornithinolytica Triggered by Ertapenem Therapy

    OXA-232 is an OXA-48-group class D β-lactamase that hydrolyzes expanded-spectrum cephalosporins and carbapenems at low levels. Clinical strains producing OXA-232 are sometimes susceptible to carbapenems, making it difficult to identify them in the clinical microbiology laboratory.

    Alina Iovleva, Roberta T. Mettus, Christi L. McElheny, Marissa P. Griffith, Mustapha M. Mustapha, A. William Pasculle, Ryan K. Shields, Vaughn S. Cooper, Yohei Doi
  • Open Access
    Comprehensive Genome Analysis of Carbapenem-Resistant Strains of <em>Raoultella</em> Species, an Emerging Multidrug-Resistant Bacterium in Hospitals
    Mechanisms of Resistance
    Comprehensive Genome Analysis of Carbapenem-Resistant Strains of Raoultella Species, an Emerging Multidrug-Resistant Bacterium in Hospitals

    We report the characterization of six carbapenem-resistant Raoultella spp. (CRRS) in our hospital and a genomic analysis of 58 publicly available isolates. CRRS isolates are sporadically identified around the world, and different transposons carrying carbapenemases were the resistant mechanisms. Mobile genetic elements play an important role in acquiring antibiotic resistance genes from the hospital.

    Xiao Yu, Beiwen Zheng, Jing Zhang, Hao Xu, Tingting Xiao, Yanzi Zhou, Shuntian Zhang, Yunying Zhu, Yuan Wang, Yonghong Xiao

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596